Articles tagged "B cells"

2022 American Transplant Congress
Lung Allograft-Resident Eosinophils Maintain Long-Term Graft Integrity by Restraining Humoral Alloimmunity
Z. Mei¹, Y. Guo¹, D. Li¹, M. Khalil¹, A. Banerjee¹, A. Gelman², D. Kreisel², A. Krupnick³
¹Department of Surgery, University of Maryland, Baltimore, Baltimore, MD, ²Washington University in St. Louis, St. Louis, MO, ³Department of Surgery, University of Maryland, Baltimore, baltimore, MD
*Purpose: The finding that eosinophils facilitate immunosuppression-mediated acceptance of murine lung allograft by downregulating alloreactive CD8+ T cells has been recently described by our group.…
2022 American Transplant Congress
Deficiency of Antibody-Suppressor CXCR5⁺CD8⁺ TCells (Not CD4⁺ T_regs) Drive High Alloantibody Production in CCR5 KO Kidney Transplant Recipients
J. L. Han¹, J. M. Zimmerer¹, Q. Zeng², S. Chaudhari¹, C. K. Breuer², G. L. Bumgardner¹
¹Dept of Surgery, The Ohio State University, Columbus, OH, ²Center for Regen. Med., The Research Institute at Nationwide Children's Hospital, Columbus, OH
*Purpose: Kidney transplant (KTx) into CCR5 KO mice is an excellent model to study AMR immunobiology due to high alloantibody (alloAb) production, rapid allograft rejection,…
2022 American Transplant Congress
Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up
A. Vo¹, J. Tang¹, N. Ammerman¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…
2022 American Transplant Congress
Transitional-1 B Cell IL-10/TNFα Ratio Risk-Stratifies Renal Transplant Patients with Early Borderline Change
A. Cherukuri, P. Randhawa, S. Hariharan, D. Rothstein
Thomas E. Starzl Transplantation Institute, UPMC, Pittsburgh, PA
*Purpose: Recent studies have shown that Banff borderline change (BLC) on allograft biopsies (Bx) is associated with decreased graft survival. However, many patients with BLC…
2022 American Transplant Congress
Bone Marrow Resident Long-Lived Plasma Cells as Source of Chronic Donor-Specific Antibodies
M. Muckenhuber, S. Pichler, A. M. Weijler, T. Wekerle
Dept. of General Surgery, Div. of Transplantation, Medical University of Vienna, Vienna, Austria
*Purpose: The importance of bone marrow resident plasma cells for long-lasting humoral immunity has been highlighted in several models for vaccination and infectious diseases. To…
2022 American Transplant Congress
Dynamic Changes of Serum Soluble B Cell Activating Factor in Kidney Transplant with De Novo Donor Specific Antibody
S. Wu¹, X. Su¹, Y. Gao¹, Y. Wei¹, Q. Ye¹, M. Huang², Y. Chen¹, J. Wang¹, Q. Zhang³, Q. Fu¹, J. Li², H. Huang², B. Xu², H. Zhang¹, L. Liu², C. Wang²
¹Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ²The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, ³Charité - Universitätsmedizin Berlin, Berlin, Germany
*Purpose: De novo donor specific antibody (dnDSA) plays a crucial role in the development of antibody mediated rejection (ABMR) and is correlated to the worse…
2022 American Transplant Congress
Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients
F. Alkhunaizi¹, M. Ellison², V. Berrich¹, M. Siegelin¹, M. Szabolcs¹, G. F. Sayer¹, N. Uriel¹, S. Restaino¹, A. Chong³, A. Zeevi², M. Habal¹
¹Columbia University Medical Center, New York, NY, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Chicago, Chicago, IL
*Purpose: Donor specific antibodies (DSA) and antibody mediated rejection (AMR) continue to limit allograft longevity after heart transplant. Effective treatments are limited and often complicated…
2022 American Transplant Congress
A Novel Immunosuppressive Compound (79-6) That Targets Bcl6 Prevents the Humoral Alloresponse
R. Kraaijeveld, D. A. Hesselink, C. C. Baan
Internal medicine - Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, Netherlands
*Purpose: BCL6, is a transcription factor involved in B cell activation and differentiation. BCL6-expressing B cells play a crucial role in the development and maintenance…
2022 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh, F. Messner, Y. Guo, G. Brandacher
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2022 American Transplant Congress
Antibody Response and Cellular Phenotyping in Kidney Transplant Recipients Following Sars-CoV-2 Vaccination
N. M. Ali¹, J. Miles², S. Mehta¹, V. Tatapudi¹, B. Lonze¹, E. Weldon¹, Z. Stewart¹, C. DiMaggio¹, J. Allen³, S. Gray-Gaillard³, S. Solis³, M. Tuen³, J. Leonard¹, R. Montgomery¹, R. Herati³
¹Transplant Institute, NYU Langone Health, New York, NY, ²CareDx, Brisbane, NY, ³NYU Langone Health, New York, NY
*Purpose: Correlates of protection for SARS-CoV-2 vaccines are not well-established in kidney transplant recipients(KTRs). Studies have highlighted the importance of neutralizing antibodies(Abs), however data suggests…

1
2
3
…
35
Next Page »